Investigation is fresh sign of breakdown in relations between Brussels and Anglo-Swedish vaccine supplier
An AstraZeneca plant has come under investigation by the Italian police at the request of Brussels in a sign of the breakdown in relations between the Anglo-Swedish vaccine supplier and the EU.
Officers were sent into the facility in the town Anagni, east of Rome, on Saturday evening after the European commission contacted the Italian government with concerns.
Continue reading...Valdis Dombrovskis, a European commission vice-president, said the commission was revising its export authorisation mechanism in order to 'preserve security of supply chains'.
Under the revised regulation, countries with a high level of vaccination coverage or those that restrict exports through law or their contracts with suppliers now risk having shipments prohibited
Continue reading...Bloc expected to assess countries’ Covid vaccination coverage and record in facilitating exports to EU
The EU is expected to take into account the level of vaccination coverage in a country and its record in facilitating exports to the bloc when deciding on whether to prohibit individual vaccine shipments to the UK and elsewhere.
The revision of the export authorisation scheme, widening the criteria that will guide Brussels’ decisions on export requests, is due to be announced on Wednesday. EU leaders will then on Thursday discuss going further in controlling vaccine distribution when they meet by videoconference.
Continue reading...PM has first dose, calling experience ‘very good, very quick’ and urging Britons to get vaccinated
Boris Johnson has received his first dose of a coronavirus vaccine at London’s St Thomas’ hospital, where last year he was treated in intensive care for Covid, and urged others to have the jab.
Related: ‘It's a good day’: enthusiasm in Berlin as AstraZeneca Covid jabs resume
Continue reading...PM welcomes vaccine safety vow, then spots new offshore home for folk trafficked here under false pretence – of getting a welcome
After a morning spent painting flowers at a primary school in his Uxbridge constituency, Britain’s prize clot returned to Downing Street to lead a press conference on clots. Blood clots to be precise.
Following the decision of some countries to suspend their Oxford AstraZeneca vaccination programmes over concerns of blood clot side-effects, Boris Johnson was happy to report that the UK’s Medicines and Healthcare products Regulatory Agency had declared the Oxford/AstraZeneca vaccine to be absolutely safe.
Continue reading...EMA says benefits outweigh risks but it is continuing to study possible link with very rare blood clotting disorder
Italy, France and several other countries will resume administering AstraZeneca jabs from Friday after Europe’s medicines regulator said the vaccine was “safe and effective” and its benefits outweighed its risks.
Germany and Portugal will resume on Monday, Spain and the Netherlands next week, while Sweden’s public health agency said it would take “a few days” to decide.
Continue reading...The Oxford/AstraZeneca coronavirus vaccine is 'safe and effective' and its benefits outweigh the risks, Europe’s medicines regulator has said. The director of the European Medicines Agency, Emer Cooke, said the agency’s safety committee had reached 'a clear scientific conclusion' and had not found that the vaccine was associated with an increase in the overall risk of blood clots
Continue reading...Biden administration has come under pressure to share vaccine, which has been authorized in other countries but not yet in US
The United States plans to send roughly 4m doses of AstraZeneca’s Covid-19 vaccine that it is not using to Mexico and Canada in loan deals with the two countries.
Mexico will receive 2.5m doses of the vaccine and Canada will receive 1.5m doses, the official said.
Continue reading...Analysis: Germany, France, Spain and Italy head an expanding list of EU countries to have put its use on hold
A host of European countries have put all vaccinations with this jab on hold, including Germany, France, Spain, Italy, Denmark, Norway and Ireland. Some others such as Estonia and Austria have suspended vaccinations from particular batches of the vaccine.
Continue reading...It’s human nature to spot patterns in data. But we should be careful about finding causal links where none may exist
Stories about people getting blood clots soon after taking the Oxford/AstraZeneca vaccine have become a source of anxiety among European leaders. After a report on a death and three hospitalisations in Norway, which found serious blood clotting in adults who had received the vaccine, Ireland has temporarily suspended the jab. Some anxiety about a new vaccine is understandable, and any suspected reactions should be investigated. But in the current circumstances we need to think slow as well as fast, and resist drawing causal links between events where none may exist.
As Ireland’s deputy chief medical officer, Ronan Glynn, has stressed, there is no proof that this vaccine causes blood clots. It’s a common human tendency to attribute a causal effect between different events, even when there isn’t one present: we wash the car and the next day a bird relieves itself all over the bonnet. Typical. Or, more seriously, someone is diagnosed with autism after receiving the MMR vaccine, so people assume a causal connection – even when there isn’t one. And now, people get blood clots after having a vaccine, leading to concern over whether the vaccine is what caused the blood clots.
Continue reading...Prof Karina Butler says Irish health authority recommendation after unproven reports of blood clotting is down to ‘an abundance of caution’
Brazil has reported 1,127 further Covid-19 deaths in the past 24 hours and 43,812 new cases of the coronavirus, the health ministry said as the pandemic’s most lethal week for the country comes to an end.
The South American country has now registered a total of 11,483,370 cases, Reuters reports.
France must do everything to avoid another lockdown as pressure on hospitals grows, prime minister Jean Castex has said as the country added more than 26,000 new cases to its tally.
Rather than send the country into a third national lockdown, the French government has implemented a 6pm nationwide curfew and weekend lockdowns in two hotspot regions while shutting shopping centres.
We have to use all weapons available to avoid a lockdown. I’ve never hid it, let’s vaccinate, protect ourselves, get tested,” Castex said on Sunday.
The situation is not getting better, there is a higher and higher number of infections and hospitals are very burdened with many patients, whose average age is getting lower and who don’t always have comorbidities.”
Continue reading...Deployment of Oxford vaccine temporarily deferred after latest reports from Norway
Ireland is suspending use of the Oxford/AstraZeneca coronavirus vaccine as a precautionary measure following further reports of blood clots in people who have received it, this time from Norway.
The deputy chief medical officer, Dr Ronan Glynn, said Ireland’s advisory body on vaccines had recommended that deployment of the AstraZeneca jab should be “temporarily deferred” with immediate effect. He stressed, though, that there was no proof that the vaccine had caused blood clots.
Continue reading...Several countries suspend inoculations but regulator says vaccine benefits outweigh its risks
The European Medicines Agency has said the Oxford/AstraZeneca Covid vaccine can continue to be used during an investigation into cases of blood clots that have prompted several European countries to pause their use of the shot.
The EMA said 30 cases of “thromboembolic events” or blood clots had been reported among 5 million people who had received the jab in Europe so far. “The vaccine’s benefits continue to outweigh its risks,” the regulator said in a statement.
Continue reading...The companies in line for the biggest gains – and the shareholders who have already made fortunes
The arrival of Covid-19 vaccines promises a return to more normal life – and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies.
Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.
Continue reading...Both countries urged to take action to avoid pile-up of unused AstraZeneca vaccine doses
Authorities in Germany and France are under pressure to come up with creative solutions to shift the AstraZeneca vaccine at higher speed in order to avoid a pile-up of unused doses over the coming weeks.
On Monday, France’s medical regulator reversed its advice not to use the AstraZeneca jab on over-65s, and Germany’s vaccination committee is coming under increasing pressure to follow suit or even scrap prioritisation altogether.
Continue reading...Regulator concedes process had ‘somehow gone wrong’ and could soon approve vaccine
Germany could soon authorise the use of the AstraZeneca vaccine for seniors after the head of the country’s vaccination committee said his body’s advice to give the Oxford-developed vaccine only to those under 65 had “somehow gone wrong”.
Unlike the European Medicines Agency or Britain’s MHRA, Germany’s Standing Committee on Vaccination (Stiko) last month recommended against the use of the AstraZeneca vaccine on seniors, citing a lack of conclusive trial data to prove its efficacy in that age group.
Continue reading...Expected shortfall of 90m doses could hit the EU’s ability to meet its target of vaccinating 70% of adults by summer
AstraZeneca has told the European Union it expects to deliver less than half the Covid-19 vaccines it was contracted to supply in the second quarter, an EU official told Reuters on Tuesday.
Contacted by Reuters, AstraZeneca did not deny what the official said, but a statement late in the day said the company was striving to increase productivity to deliver the promised 180m doses.
Continue reading...A year ago, two scientists began work on the response to a new virus. Now, as their vaccine is being given to millions, they tell of their incredible 12 months
Exactly a year ago, Oxford University scientists launched a joint enterprise that is set to have a profound impact on the health of our planet. On 11 February, research teams led by Professor Andy Pollard and Professor Sarah Gilbert – both based at the Oxford Vaccine Centre – decided to combine their talents to develop and manufacture a vaccine that could protect people from the deadly new coronavirus that was beginning to spread across the world.
A year later that vaccine is being administered to millions across Britain and other nations and was last week given resounding backing by the World Health Organization. The head of the WHO’s department of immunisation, vaccines and biologicals, Professor Kate O’Brien, described the jab as “efficacious” and “an important vaccine for the world”.
Continue reading...The Anglo-Swedish firm already had a strong lineup of cancer drugs when vaccine success gave it a further boost
Before the pandemic, AstraZeneca was highly regarded in the business and pharmaceutical world – seen as one of the UK’s best companies. Now, thanks to Britain’s successful vaccine programme, it is a household name.
The Anglo-Swedish firm, which publishes annual results on Thursday, has sprung to prominence as maker of one of the world’s first Covid-19 vaccines, approved for use in the UK, EU and India. Inevitably, headlines have followed. AstraZeneca has been the focal point of the vaccine supply wars between the UK and the EU and has, as part of that row, faced questions over the effectiveness of the jab in the over-65s.
Continue reading...University of the Witwatersrand and Oxford University research shows vaccine has reduced efficacy against mutation
British drugmaker AstraZeneca said on Saturday that its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of Covid-19, based on early data from a trial.
The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Continue reading...